This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (28)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Randomized, Double-blind, Placebo-Controlled Trial

Frank A. Lederle, MD; Robert E. Pluhar, PharmD; Anne M. Joseph, MD, MPH; Dennis E. Niewoehner, MD

Arch Intern Med. 1987;147(12):2201-2203.

Abstract
• Systemic corticosteroids are effective in the treatment of acute asthma, but the optimal schedule for steroid withdrawal following an asthma exacerbation has not been determined. This study was designed to test the hypothesis that tapering the corticosteroid dosage over a longer period of time reduces the number of reexacerbations. Non-steroid-dependent adult men hospitalized for asthma exacerbations during a one-year period (n = 43) were randomly assigned to corticosteroid tapering regimens of one or seven weeks, following an eight-day course of high-dose corticosteroid therapy. There were no significant differences between the long-taper and short-taper groups in rate of reexacerbation (41% vs 52%) or readmission (22% vs 21%) during the 12-week study period. Patients who did not have a reexacerbation during the 12 weeks were evaluated with spirometry, with no significant differences occurring between the two groups. More patients in the long-taper group reported corticosteroid side effects (41% vs 14%). Patients who required mechanical ventilation during the initial hospitalization (n = 7), or who reported more than two days of worse than usual dyspnea in the 12-week period (n = 20), had high rates of reexacerbation (86% and 80%, respectively). These results provide reasonable certainty (90%) that a long taper does not result in a large reduction (50% or more) in reexacerbations compared with a short taper. We conclude that the relapse rate is high in this population regardless of the corticosteroid tapering regimen used, and that a long taper does not appear to provide enough benefit to justify its routine use.

(Arch Intern Med 1987;147:2201-2203)

Author Affiliations
From the Department of Medicine (Drs Lederle, Joseph, and Niewoehner) and the Pharmacy Service (Dr Pluhar), the Minneapolis Veterans Administration Medical Center and the University of Minnesota, Minneapolis.

Footnotes
Accepted for publication Sept 8, 1987.

Reprint requests to the Division of General Internal Medicine, Department of Medicine 111-0, Minneapolis Veterans Administration Medical Center, 54th Street and 48th Avenue South, Minneapolis, MN 55417 (Dr Lederle).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Global strategy for asthma management and prevention: GINA executive summary
Bateman et al.
Eur Respir J 2008;31:143-178.
ABSTRACT | FULL TEXT  

Effect of Systemic Glucocorticoids on Exacerbations of Chronic Obstructive Pulmonary Disease
Niewoehner et al.
NEJM 1999;340:1941-1947.
ABSTRACT | FULL TEXT  

Inhaled Budesonide in Addition to Oral Corticosteroids to Prevent Asthma Relapse Following Discharge From the Emergency Department: A Randomized Controlled Trial
Rowe et al.
JAMA 1999;281:2119-2126.
ABSTRACT | FULL TEXT  

Pharmacotherapy for Asthma and Chronic Obstructive Pulmonary Disease: Current Thinking, Practices, and Controversies
Skorodin
Arch Intern Med 1993;153:814-828.
ABSTRACT